हिंदी में पढ़ें

pharmaceutical

South Korea's pharmaceutical, biotechnology exports surge 55% in H1

South Korea's pharmaceutical, biotechnology exports surge 55% in H1

Sat, Jun 29, 2024

In the first six months of the year, the country exported 4.5 trillion won ($3.26 billion) worth of pharmaceutical and biotechnologies, up 55 per cent from 2.9 trillion won (about $2.09 billion) for the same period last year, according to the data from the Korea Pharmaceutical and Bio-Pharma Manufacturers Association.

Dr Reddy's Laborataries signs in-licensing pact with Ingenus Pharmaceuticals for cancer treatment injection

Dr Reddy's Laborataries signs in-licensing pact with Ingenus Pharmaceuticals for cancer treatment injection

Wed, Jun 12, 2024

Dr Reddy's Laboratories Inc and US-based Ingenus Pharmaceuticals, LLC have entered into license agreement to commercialise cancer-treating Cyclophosphamide injection.

Orchid Pharma gets DCGI nod to market antibiotic drug combination

Orchid Pharma gets DCGI nod to market antibiotic drug combination

Thu, Jun 06, 2024

The Drug Controller General of India (DCGI) has granted permission to manufacture and market the finished dosage form of Cefepime and Enmetazobactam as a dry powder injectable, the drug firm said in a statement.

TRENDING NOW

We have a wide trade deficit with China, says Shaktikanta Das

We have a wide trade deficit with China, says Shaktikanta Das

Mon, Feb 13, 2017

Shaktikanta Das said that they are working to increase their exports in China and to decrease the trade deficit.

GlaxoSmithKline Pharma's Q3 net profit down 33%

GlaxoSmithKline Pharma's Q3 net profit down 33%

Sat, Feb 11, 2017

The company reported net profit of Rs 52.95 crore, a drop of 32.91% from Rs 78.93 crore in the corresponding period of the previous year.

Lupin's Q3 net profit rise by 21%; shares trade high

Lupin's Q3 net profit rise by 21%; shares trade high

Thu, Feb 09, 2017

Pharmaceutical-major Lupin on Thursday reported 21% rise in net profit during the quarter ended on December 31.

Q3FY17: Dr Reddy's Laboratories' net profit down 19% at Rs 470 crore

Q3FY17: Dr Reddy's Laboratories' net profit down 19% at Rs 470 crore

Sat, Feb 04, 2017

GV Prasad, Co-chairman of Dr Reddy's Laboratories said, "Our performance in Q3 has delivered a modest sequential revenue growth of 3% over the previous quarter. Our EBITDA has improved significantly from the last quarter to Rs 8.8 billion, on the back of enhanced emphasis on operational efficiencies and controlling of SG&A cost across all our business."

Divi's Laboratories report 9% rise in net profit in Q3

Divi's Laboratories report 9% rise in net profit in Q3

Sat, Feb 04, 2017

Updating on US-FDA inspection, Divi's Lab said, "It has filed its comprehensive response to the observations of the FDA regulator within the stipulated time. Now it awaits for review from the US pharma regulator.

Glenmark Pharma's Q3 net profit rise by 143% to Rs 477 crore

Glenmark Pharma's Q3 net profit rise by 143% to Rs 477 crore

Thu, Feb 02, 2017

The company's total income increased to Rs 2549.5 crore in Q3FY17 as compared to Rs 1780.4 crore in Q3FY16.

Natco Pharma drops as USFDA makes six observations

Natco Pharma drops as USFDA makes six observations

Wed, Jan 25, 2017

Shares of Natco Pharma dropped 0.22% on NSE Nifty after the company said that USFDA conducted an inspection at its pharmaceutical factory in Kothur, near Hyderabad between January 16-24, 2017.

Pharma Q3: FDA inspection, US pricing market key

Pharma Q3: FDA inspection, US pricing market key

Thu, Jan 12, 2017

Piyush Nahar and Anurag Mantry analysts of Jefferies said, “We expect another muted quarter for the pharma sector led by weakness in US business. USFDA inspections and pricing in US market will continue to dominate the results. Recent comments from global peers have indicated that pricing scenario will likely remain unchanged in 2017.”

Zydus Cadila acquires six brands from American pharma MSD

Zydus Cadila acquires six brands from American pharma MSD

Wed, Dec 28, 2016

Though the companies have not disclosed the financial details of the deal.

Divi's laboratories drops over 10% on USFDA reports

Divi's laboratories drops over 10% on USFDA reports

Mon, Dec 26, 2016

Pharmaceutical major Divi's Laboratories Ltd continued to fall on Monday with the stock cracking over 10%, or Rs 85.75 per share.

Sun Pharma arm picks up 14.6% stake in US company for $13 million

Sun Pharma arm picks up 14.6% stake in US company for $13 million

Fri, Dec 23, 2016

"...One of the wholly-owned subsidiaries of the company has acquired 13,000,000 Series B preferred stock of scPharmaceuticals Inc (equivalent to 14.58% fully diluted equity stake on conversion) by way of allotment," Sun Pharmaceutical Industries said in a BSE filing.

Sun Pharma to acquire oncology product from Novartis for $175 million; stock up 0.5%

Sun Pharma to acquire oncology product from Novartis for $175 million; stock up 0.5%

Thu, Dec 22, 2016

"Odomzo gives us an opportunity to meaningfully expand our already established branded dermatology business and support our expansion into branded oncology with a launched brand," Kirti Ganorkar, Global Head Business Development at Sun Pharma, said.

Fire accident at Biocons' one Syngene Lab, shares tumble

Fire accident at Biocons' one Syngene Lab, shares tumble

Tue, Dec 13, 2016

It said, "Syngene is in the process of assessing the extent of damage to the building and equipment and also implementating a business continuity plan to minimize impact on operations."

M&A activity to fuel growth for India's pharma sector

M&A activity to fuel growth for India's pharma sector

Mon, Dec 12, 2016

Kaustubh Chaubal, a Moody's Vice President and Senior Analyst said, "The drive for overseas expansion comes amid the consolidation of the global pharmaceutical industry, as drug companies look to boost their product and pipeline diversity, scale and pricing power."

Indian pharma industry facing growth headwinds: ICRA

Indian pharma industry facing growth headwinds: ICRA

Thu, Dec 08, 2016

"In spite of these ongoing challenges, several Indian pharma companies are increasing their R&D spend, targeting pipeline of specialty drugs, niche molecules and complex therapies," ICRA said.

Sun Pharma to acquire Russia's JSC Biosintez; shares up

Sun Pharma to acquire Russia's JSC Biosintez; shares up

Wed, Nov 23, 2016

“With this move, we plan to acquire the product portfolio and local manufacturing capability in Russia which would help in expanding our presence in Russia and serving Russia pharmaceutical market more effectively,” Sun Pharma said in a statement.

Higher spending, urbanisation to boost domestic pharma markets: Fitch

Higher spending, urbanisation to boost domestic pharma markets: Fitch

Tue, Nov 15, 2016

Increase in consumer spending in India would provide a boost to domestic pharmaceutical companies over the medium term, credit rating agency Fitch said.

Sun Pharma Q2 net profit rises by 90%; India sales up by 11%

Sun Pharma Q2 net profit rises by 90%; India sales up by 11%

Fri, Nov 11, 2016

Pharma-giant Sun Pharma reported consolidated net profit of Rs 2471.11 crore for the second quarter September 30, 2016, recording robust rise of 90.20% year-on-year (yoy) and 8.96% quarter-on-quarter (qoq).

Cipla Quality Chemical Industries plans to enter IPO market

Cipla Quality Chemical Industries plans to enter IPO market

Fri, Nov 11, 2016

Cipla said," Certain shareholders may consider selling down part or all of their stake to enable sufficient free float and liquidity.The Cipla group intends to continue holding the majority of stake and control in the subsidiary."

What would a Hillary Clinton win mean for Indian Pharma?

What would a Hillary Clinton win mean for Indian Pharma?

Mon, Nov 07, 2016

The global generics sector saw a significant de-rating in YTD (year-to-date) in the CY2016 with 1-year forward P/E (price over equity) contracting by 34%, with the past one month itself witnessing an 11%.

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x